I think that this is an important part that we need to examine.
A brief example—again, a boots-on-the-ground example, I would say—is that we had a recent patient who was in the hospital for chemotherapy. They were prescribed a pill. Their prescription went outside of the hospital to be filled and came back in the hospital to be administered. Now what do we have? We have a $10,000 monthly bill where, according to the Canada Health Act, it was prescribed. The hospital went out to fill it, and now you have the public system and the employer system confused as to who should be responsible to pay.
The bottom line is that a therapy like this that is high cost is allowing this person to leave that hospital and be productive at work and healthy long term. This pipeline of drugs that is coming and available to Canada.... We want to make sure that we can work together to cost-effectively build a national strategy for high-cost and rare diseases.
Thank you for the question.